The use of Infuse even among on-label applications has recently come into question as well because some feel the field is lacking evidence-based literature proving BMP creates better outcomes. Without solid backing from strong studies, hospitals and insurance companies are hard-pressed to approve the use of Infuse, since it is considerably more expensive than the alternatives.
However, InVivo has focused its efforts on both regenerative medicine and neuroprotection. Its scaffolds are designed to mitigate inflammation and prevent further cell death after SCI as well as support the repair and neuroplasticity recovery process. Co-founded by CEO and CFO Frank Reynolds and Robert Langer, ScD in 2005, InVivo Therapeutics and its scientific team have made incredible progress over the past few years and are now poised to bring the technology to human patients, which has created a stir in the global medical community.
Surgeons should consider the ability to concentrate platelets and leukocytes with sensitivity to pathologic conditions during platelet-rich plasma injection preparation, according to a study published in The American Journal of Sports Medicine.